Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Enliven Therapeutics, Inc.

NASDAQ: ELVN · Life Sciences · 8 alerts · CIK 1672619

Share price
$47.62Close, Nov 16
Market cap
$3.5B
Shares outstanding
73.6MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Enliven Therapeutics, Inc. filings on SEC EDGAR ↗

5:54 PM ET Form 4
Insider Selling

Enliven Therapeutics CFO Benjamin Hohl Sells $232K of Stock

Benjamin Hohl, CFO, sold 6,018 shares of Enliven Therapeutics, Inc. at $38.48 a share, worth $232K in total on Oct 19, 2026. Shares held after the trade: 38,000 (-13.7%).

Value
$232K
Shares
6,018
Price
$38.48
Role
CFO
Holding change
-13.7%
Trade date
Oct 19, 2026
5:52 PM ET Form 4
Insider Selling

Enliven Therapeutics CMO Helen Louise Collins Sells $192K of Stock

Helen Louise Collins, CMO, sold 5,000 shares of Enliven Therapeutics, Inc. at $38.47 a share, worth $192K in total on Oct 19, 2026. Shares held after the trade: 25,000 (-16.7%).

Value
$192K
Shares
5,000
Price
$38.47
Role
CMO
Holding change
-16.7%
Trade date
Oct 19, 2026
4:57 PM ET Form 4
Insider Selling

Enliven Therapeutics Director J. Scott Garland Sells $607K of Stock

J. Scott Garland, Director, sold 13,000 shares of Enliven Therapeutics, Inc. at $46.67 a share, worth $607K in total on Oct 1, 2026. Shares held after the trade: 0 (-100.0%).

Value
$607K
Shares
13,000
Price
$46.67
Role
Director
Holding change
-100.0%
Trade date
Oct 1, 2026
5:24 PM ET Form 4
Insider Selling

Enliven Therapeutics CFO Benjamin Hohl Sells $303K of Stock

Benjamin Hohl, CFO, sold 6,018 shares of Enliven Therapeutics, Inc. at $50.03 to $51.49 a share (average $50.35) in 3 transactions, worth $303K in total on Sep 17, 2026. Shares held after the trade: 38,000 (-0.8%).

Value
$303K
Shares
6,018
Average price
$50.35
Role
CFO
Holding change
-0.8%
Trade date
Sep 17, 2026
5:22 PM ET Form 4
Insider Selling

Enliven Therapeutics CMO Helen Louise Collins Sells $252K of Stock

Helen Louise Collins, CMO, sold 5,000 shares of Enliven Therapeutics, Inc. at $50.03 to $51.48 a share (average $50.35) in 3 transactions, worth $252K in total on Sep 17, 2026. Shares held after the trade: 25,000 (-1.0%).

Value
$252K
Shares
5,000
Average price
$50.35
Role
CMO
Holding change
-1.0%
Trade date
Sep 17, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.